Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricema

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 8, 2015, Pages 887-892

  Nishizawa, Tohru ^a   Taniura, Takehito ^b   Nomura, Shosaku ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b Daiwa   (Japan)

Author keywords

Adiponectin; Febuxostat; Hyperuricemia; Platelet derived microparticle; sP selectin

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; FEBUXOSTAT; INTERLEUKIN 6; URIC ACID; XANTHINE OXIDASE; ADIPOQ PROTEIN, HUMAN; ANTIGOUT AGENT; IL6 PROTEIN, HUMAN;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; PLATELET MICROPARTICLE; PRIORITY JOURNAL; THROMBOSIS; URIC ACID BLOOD LEVEL; ADULT; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; CAROTID ARTERY THROMBOSIS; CASE CONTROL STUDY; CHEMISTRY; COMPLICATION; DRUG EFFECTS; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; PATHOLOGY; THROMBOCYTE; VERY ELDERLY;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD PLATELETS; CAROTID ARTERY THROMBOSIS; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; FEBUXOSTAT; FEMALE; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; INTERLEUKIN-6; MALE; MIDDLE AGED; URIC ACID; XANTHINE OXIDASE;

EID: 84947048821     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000335     Document Type: Article

References (38)

1. Fagugli RM, Gentile G, Ferrara G, Brugnano R. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol 2008; 70:523-526.
2. Kaya EB, Yorguna H, Canpolata U, Hazirolan T, Susman H, Ülgen A, et al. Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography. Atherosclerosis 2010; 213:178-183.
3. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107:1991-1997.
4. Park SH, Shin WY, Lee EY, Gil HW, Lee SW, Lee SJ, et al. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ J 2011; 75:692-697.
5. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res 2008; 123:8-23.
6. Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. J Intensive Care 2015; 3:2-11.
7. Miyazaki Y, Nomura S, Miyake T, Kagawa H, Kitada C, Taniguchi H, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996; 88:3456-3464.
8. Sinauritz EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97:425-434.
9. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte- derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation 2000; 102:1296-1301.
10. Nomura S, Shouzu A, Omoto S, Inami N, Shimazu T, Satoh D, et al. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients. Blood Coagul Fibrinolysis 2009; 20:440-447.
11. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79-83.
12. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-1935.
13. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278:45021-45026.
14. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46:1543-1549.
15. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450-2461.
16. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease; molecular mechanisms and pathophysiological implications. J Physiol 2004; 555:589-606.
17. Nakai K, Kadiiska MB, Jiang JJ, Stadier K, Mason RP. Free radical production requires both inducible nitric oxide synthase and xanthine oxidase in LPS-treated skin. Proc Natl Acad Sci U S A 2006; 103:4616-4621.
18. Nomura J, Busso N, Ives A, Tsujimoto S, Tamura M, So A, et al. Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase- 1-mediated inactivation of JNK. PLoS One 2013; 8:e75527.
19. Tatuo H, Iwao O. A repeated oraladministration study of febuxostata (TMX-67), a nonpurine-selective inhibitor of xanthine oxidase in patients with impaired renal function in Japan. J Clin Rheumatol 2011; 17:S27-S34.
20. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol 2011; 17:S50-S56.
21. Osumi K, Ozeki Y, Saito S, Nagamura Y, Ito H, Kimura Y, et al. Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost 2001; 85:326-330.
22. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18:523-530.
23. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2:126-130.
24. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, et al. Uric acid and inflammatory markers. Eur Heart J 2006; 27:1174-1181.
25. Sezai A, Soma M, Nakata K, Hada M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Cir J 2013; 77:2043-2049.
26. Shimazu T, Inami N, Satoh D, Kajiura T, Yamada K, Iwasaka T, et al. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients. J Thromb Thrombolysis 2009; 28:429-435.
27. Nomura S, Shouzu A, Taomoto K, Togane Y, Goto S, Ozaki Y, et al. Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan. J Atherscler Thromb 2009; 16:878-887.
28. Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress- induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158:277-287.
29. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001; 115:3-12.
30. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011; 60:1258-1269.
31. Kushiyama A, Okubo H, Sakoda H, Kikuchi T, Fujishiro M, Sato H, et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol 2012; 32:291-298.
32. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88:3236-3240.
33. Maddux BA, See W, Lawrence JC Jr, Goldfine AL, Goldfine ID, Evans JL. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of (-lipoic acid. Diabetes 2001; 50:404-410.
34. Matsuoka T, Kajimoto Y, Watada H, Kaneko H, Kishimoto M, Umayahara Y, et al. Glycation-dependent, reactive oxygen species- mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 1997; 99:144-150.
35. Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 1998; 47:1562-1569.
36. Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006; 341:549-556.
37. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114:1752-1761.
38. Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, et al. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wavw velocity in patients with severe chronic tophaceous gout. Rheumatol Int 2014; 34:101-109.